Lifevantage Corp LFVN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants. We sell our products in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland, and Portugal. We also sell our products in a number of countries to customers for personal consumption only.

Last close 5.86 2026-10-23
Market cap $73.4M 2026-06-30 share count
52-week range 3.90 - 11.71

Valuation FY2026 figures against the last close

P/S0.4x
P/E14.7x
P/FCF11.0x
EV/EBITDA8.3x
Dividend yield3.2%
Diluted EPS0.40

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $182.6M$228.5M$200.2M$213.4M$206.4M$220.2M$232.9M$226.0M$203.2M$199.5M
Cost of revenue $41.0M$44.9M$41.4M$43.4M$38.1M$38.2M$38.0M$38.0M$34.8M$33.5M
Gross profit $141.6M$183.7M$158.7M$170.0M$168.3M$182.0M$195.0M$188.0M$168.4M$166.0M
R&D $1.0M$1.4M$700.0K$600.0K$700.0K$700.0K$900.0K$1.1M$1.2M$1.1M
SG&A $58.4M$69.2M$68.5M$71.1M$63.4M$60.8M$67.9M$69.6M$59.8M$64.9M
Total operating expenses $135.5M$171.5M$154.4M$165.8M$160.7M$164.4M$179.5M$178.2M$158.0M$161.6M
Operating income $6.1M$12.2M$4.3M$4.3M$7.6M$17.6M$15.5M$9.8M$10.3M$4.4M
Interest expense ——$430.0K$198.0K$10.0K$17.0K$120.0K$323.0K$456.0K$570.0K
Pre-tax income $6.1M$12.2M$4.3M$4.0M$4.7M$17.2M$14.7M$9.2M$9.5M$2.9M
Income tax $994.0K$2.4M$1.4M$1.5M$1.6M$4.3M$3.1M$1.8M$3.8M$1.3M
Net income $5.1M$9.8M$2.9M$2.5M$3.1M$12.9M$11.5M$7.4M$5.8M$1.6M
EPS, basic 0.400.800.240.200.240.920.820.530.410.12
EPS, diluted 0.400.750.230.200.240.900.790.500.410.11
Shares, diluted (wtd. avg.) 12.7M13.0M13.0M12.6M13.1M14.3M14.6M15.0M14.1M14.1M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $14.9M$20.2M$16.9M$21.6M$20.2M$23.2M$22.1M$18.8M$16.7M$11.5M
Receivables $3.0M$3.3M$2.9M$1.6M$3.3M$2.9M$2.6M$2.1M$2.1M$1.3M
Inventory $16.2M$20.7M$15.1M$16.1M$16.5M$16.1M$13.9M$13.8M$13.6M$16.6M
Total current assets $38.3M$50.9M$37.6M$44.3M$47.0M$48.1M$43.9M$43.2M$38.9M$35.5M
Property, plant and equipment $7.3M$6.2M$7.8M$9.1M$9.5M$11.1M$7.2M$7.1M$6.6M$3.1M
Goodwill $465.0K$0————————
Other intangibles $3.1M$245.0K$323.0K$455.0K$587.0K$719.0K$851.0K$983.0K$1.1M$1.2M
Total assets $62.1M$72.0M$60.3M$66.1M$70.7M$78.7M$58.9M$55.3M$51.1M$45.2M
Accounts payable $5.2M$4.6M$5.9M$3.5M$7.5M$6.7M$3.5M$5.2M$3.8M$4.8M
Short-term debt ——————$0$1.5M$2.0M$2.0M
Total current liabilities $20.2M$27.2M$22.3M$19.6M$25.7M$25.2M$25.0M$26.2M$23.8M$23.4M
Long-term debt ———————$0$3.4M$5.4M
Total liabilities $28.5M$37.3M$34.3M$31.5M$39.2M$41.9M$25.6M$28.1M$29.2M$30.7M
Retained earnings -$103.5M-$104.1M-$108.7M-$98.3M-$98.4M-$92.3M-$93.3M-$100.0M-$102.7M-$107.0M
Total equity $33.6M$34.6M$26.0M$34.6M$31.5M$36.8M$33.3M$27.2M$21.9M$14.5M

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $10.2M$11.9M$12.2M$6.8M$8.0M$16.3M$18.3M$17.8M$13.3M$6.6M
Depreciation and amortisation $2.8M$3.2M$3.6M$3.6M$3.3M$3.5M$2.8M$1.9M$1.3M$1.6M
Stock-based compensation $2.3M$5.7M$3.3M$3.2M$1.8M$2.0M$4.9M$5.5M$3.2M$2.6M
Capital expenditure $3.6M$1.4M$2.2M$3.1M$1.5M$3.7M$2.7M$2.5M$4.6M$1.1M
Investing cash flow -$7.3M-$1.4M-$2.2M-$3.1M-$1.5M-$3.7M-$2.7M-$4.5M-$4.6M-$1.1M
Financing cash flow -$7.8M-$7.6M-$14.4M-$2.4M-$9.0M-$11.5M-$12.4M-$11.1M-$3.5M-$2.0M
Dividends paid $2.3M$2.1M$6.9M$1.6M$378.0K$0$0———
Buybacks $2.0M$3.1M$6.4M$822.0K$8.8M$11.9M$5.4M$4.7M$1.5M$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-371257.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. 0 100M 200M 300M Revenue, FY2017: 199.5M Gross profit, FY2017: 166M Net income, FY2017: 1.6M Revenue, FY2018: 203.2M Gross profit, FY2018: 168.4M Net income, FY2018: 5.8M Revenue, FY2019: 226M Gross profit, FY2019: 188M Net income, FY2019: 7.4M Revenue, FY2020: 232.9M Gross profit, FY2020: 195M Net income, FY2020: 11.5M Revenue, FY2021: 220.2M Gross profit, FY2021: 182M Net income, FY2021: 12.9M Revenue, FY2022: 206.4M Gross profit, FY2022: 168.3M Net income, FY2022: 3.1M Revenue, FY2023: 213.4M Gross profit, FY2023: 170M Net income, FY2023: 2.5M Revenue, FY2024: 200.2M Gross profit, FY2024: 158.7M Net income, FY2024: 2.9M Revenue, FY2025: 228.5M Gross profit, FY2025: 183.7M Net income, FY2025: 9.8M Revenue, FY2026: 182.6M Gross profit, FY2026: 141.6M Net income, FY2026: 5.1M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue $199.5M $203.2M $226.0M $232.9M $220.2M $206.4M $213.4M $200.2M $228.5M $182.6M
Gross profit $166.0M $168.4M $188.0M $195.0M $182.0M $168.3M $170.0M $158.7M $183.7M $141.6M
Net income $1.6M $5.8M $7.4M $11.5M $12.9M $3.1M $2.5M $2.9M $9.8M $5.1M

Recent filings and events

  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%